The most negative interaction was the one found between known antagonists BRAF and NRAS in melanoma (Curtin et al., 2005), while the most positive interactions included those between AURKA gain, APC and TP53 mutations in colorectal cancer (Figure 2d). The gene discussed is AURKA; the disease is colorectal cancer.